University of South Carolina

Scholar Commons
Theses and Dissertations
2018

Assessing the Barriers to Cardiac Care in Carriers of Duchenne
and Becker Muscular Dystrophy
Lauren Renae Eekhoff
University of South Carolina

Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Medical Genetics Commons

Recommended Citation
Eekhoff, L.(2018). Assessing the Barriers to Cardiac Care in Carriers of Duchenne and Becker Muscular
Dystrophy. (Doctoral dissertation). Retrieved from https://scholarcommons.sc.edu/etd/4463

This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please
contact digres@mailbox.sc.edu.

Assessing the Barriers to Cardiac Care in Carriers of Duchenne and Becker Muscular
Dystrophy
by
Lauren Renae Eekhoff
Bachelor of Science
Dordt College, 2016

Submitted in Partial Fulfillment of the Requirements
For the Degree of Master of Science in
Genetic Counseling
School of Medicine
University of South Carolina
2018
Accepted by:
Janice Edwards Director of Thesis
Ann Martin, Reader
EJ Prijoles, Reader
Cheryl L. Addy, Vice Provost and Dean of the Graduate School

© Copyright by Lauren Eekhoff, 2018
All Rights Reserved.

ii

ACKNOWLEDGEMENTS
Thank you to everyone who made this project and my time in graduate school
possible. To my professors, supervisors, friends, and parents—you have all influenced
me and made me into the genetic counselor I am today. I cannot thank you enough for
your support.

iii

ABSTRACT
Duchenne and Becker muscular dystrophy (DBMD) are X-linked conditions due
to mutations within the dystrophin gene that cause progressive muscle weakness,
respiratory insufficiency, and cardiomyopathy in affected males. Approximately twothirds of women who have a son with DBMD are carriers of the condition. Carriers
typically do not manifest muscular symptoms but are at risk for cardiac abnormalities
such as dilated cardiomyopathies. The American Academy of Pediatrics (AAP)
recommends that carriers of DBMD receive a complete cardiac evaluation by a
cardiologist that includes an echocardiogram and electrocardiogram (EKG) with reevaluation every five years. According to a recent study33, as many as 35.6% of carriers
are not adhering to the AAP recommendations despite having knowledge of their carrier
status. Limited research has been conducted into the barriers that carriers face in
accessing recommended cardiac screening. We surveyed 60 carriers of DBMD and
conducted semi-structured telephone interviews with 11 carriers who in the last five years
either had not seen a cardiologist, had an echocardiogram, or had an EKG to determine
the perceived challenges that carriers face in obtaining appropriate cardiac care. From the
interviews, seven major themes emerged: 1) a lack of awareness among healthcare
providers about cardiac risks 2) a responsibility among carriers for self-education and
self-advocacy 3) frustration with misinformation received 4) a lack of concern due to lack
of family history and/or a perceived healthy lifestyle 5) a lack of information-sharing
with other carriers in the family 6) a priority of the healthcare needs of family members
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over personal healthcare needs and 7) a belief that conversations about carrier status
should begin at a younger age. Increased awareness, health education regarding risks for
carriers, and advocacy efforts are needed for healthcare providers and carriers in order to
ensure that this entire population receives the cardiac care they need.
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CHAPTER 1:
LITERATURE REVIEW
1.1 Molecular mechanism of disease
Duchenne and Becker muscular dystrophy (DBMD) are neuromuscular disorders
known as dystrophinopathies, caused by mutations within the dystrophin gene located on
the X chromosome at Xp21.1 and inherited in an X-linked recessive fashion.1 Dystrophin
is one of the largest known genes at 2.2 Mb and is comprised of 79 exons. The dystrophin
gene contains three promoters: M, B, and P. The M promoter encodes for a rod-shaped
dystrophin protein which is found primarily in skeletal and cardiac muscle. Small
amounts of dystrophin are also found in nerve cells in the brain; however, the exact
function of the protein in the brain is not entirely known. The B promoter is responsible
for production of dystrophin in the brain while the P promoter produces dystrophin
expressed specifically in Purkinje cells in the brain.2
Dystrophin found in skeletal and cardiac muscle functions in the dystroglycan
complex (DGC) to connect intracellular actin filaments at the N-terminus to
glycoproteins of the sarcolemma at the C-terminus. The DGC is a complex made up of
integral membrane proteins as well as peripheral proteins that works to provide support
for cardiac or skeletal muscle cells during contraction by connecting actin filaments to
the extracellular matrix (ECM). Dystrophin functions to stabilize the plasma membrane
by carrying signals from sarcolemma contractions to the ECM.2 A figure representation
of the DGC and its associated proteins is shown in Figure 1.1.
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Figure 1.1 The dystroglycan complex2
Due to its large size, the dystrophin gene is highly susceptible to mutations.
Different types of muscular dystrophies arise from mutations within the dystrophin
protein or within any of the other DGC-associated proteins. Exonic deletions comprise
65% of all dystrophin mutations. Meanwhile, exonic duplications represent up to 10% of
all dystrophin mutations. Both exonic duplications and deletions are traditionally detected
previously by PCR analysis and more recently, by MLPA and aCGH analysis.3 Exonic
duplications and deletions tend to be present at “hot spots” within the gene located in
exons 45-53 which ultimately result in a frameshift. Small mutations such as nonsense
and missense mutations, microdeletions, splice site mutations, and insertions make up the
remaining 25-30%. These small mutations are undetectable by PCR but can be detected
using techniques such as Sanger sequencing and next generation sequencing (NGS).
Point mutations are not bound by hot spots and have been observed to be randomly
distributed across the whole dystrophin gene. However, missense mutations have been
found mostly at the N and C-termini.4 A lack of functional dystrophin due to a mutation
compromises the membranes of the skeletal and cardiac muscle cells, and the cells are at
2

an increased risk for stress-induced damage from contraction. A damaged plasma
membrane leads to an increase in calcium entering into the cell which results in cell death
and the resulting phenotypic muscle weakness and wasting.2
1.2 Duchenne muscular dystrophy (DMD)
Affecting between 1 in 3802 to 1 in 6291 boys in the United States, DMD is a
progressive muscle-wasting disorder.5 DMD is the most severe of the childhood muscular
dystrophies.1 Over 1000 mutations have been identified in the dystrophin gene that are
responsible for causing DMD with a penetrance of 100%.6 Pathogenic mutations in DMD
cause a lack of dystrophin protein production which in turn cause severe, early-onset
symptoms in DMD.7
Clinically, absent dystrophin protein can present initially as motor delays and
hypotonia.8 Calf pseudohypertrophy, Gower maneuver, and toe walking or an abnormal
gait will present between the ages of two and five.9 As the disorder progresses, the risk
increases to develop additional symptoms such as attention deficit hyperactivity disorder,
autism, and obsessive-compulsive disorder suggesting a potential effect on
neurocognitive function. Not much is known about the role of dystrophin in
neurocognitive disorders; however, dystrophin is suspected to work closely with Purkinje
fibers in the brain. In fact, approximately one-third of those diagnosed with DMD will
experience a cerebellar function-related disorder like dyslexia, mild intellectual disability,
or impairment in verbal working memory or in performing motor tasks.10 Additionally,
because this is a progressive disorder, most boys with DMD will be wheelchair-bound by
the age of twelve. Scoliosis and respiratory insufficiency are common with increasing
age.
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Cardiac involvement is present in almost all individuals with DMD. These cardiac
abnormalities can include dilated cardiomyopathy and arrhythmia. Heart muscle wasting
is the cause of dilated cardiomyopathy which usually begins in the left ventricle and
occurs when the cardiac muscle thins and is unable to pump adequate amounts of blood
to the body. Myocardial fibrosis is also associated with dysfunction with the left ventricle
and is one of the most common histological signs of heart failure.11,12 Cardiac
involvement often presents at approximately ten years of age and will affect almost all
boys after age 18. Pre-clinical detection is possible through electrocardiograph and
echocardiograph findings. Due to low physical activity with increasing age, most boys
are relatively asymptomatic in regard to cardiac manifestation.13 However, if no steroid
therapy is administered, death typically occurs in the early twenties due to congestive
heart failure and can be predicted by the level of progressing respiratory insufficiency.14
1.3 Becker muscular dystrophy (BMD)
Becker muscular dystrophy is less frequent in the U.S. population than DMD and
generally has milder symptoms. Compared to DMD, the mutations that result in BMD
keep the transcript within the reading frame causing a protein that is abnormal or present
in reduced amount instead of completely absent.7 Boys with BMD will typically present
later in childhood around age twelve with limb girdle weakness and calf hypertrophy.
However, BMD is a variable disorder. Some individuals present with muscle weakness
later in life into mid to late adulthood, and some reported variants only cause weakness in
the quadriceps or weakness as the result of exercise. Cognition is generally not impaired
in cases of BMD. Individuals with BMD will generally remain ambulant much longer
than those with DMD but are also at an increased risk for cardiomyopathy.14
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Additionally, death does not usually occur until the fourth or the fifth decade of life.
Cardiomyopathy is often the cause of death in both DMD and BMD.7
1.4 Current management strategies
There is currently no cure for muscular dystrophy. Those with muscular
dystrophy require a multidisciplinary team to manage their symptoms including yearly
visits to neurologists, cardiologists, pulmonologists, physical and occupational therapists,
and nutritionists.14 Glucocorticosteroids are often the course of treatment used to
maintain muscle strength and slow muscle wasting in addition to maintaining lung
function, prolonging ambulation, and reducing the incidence of scoliosis.15 The two most
common corticosteroids implemented are prednisone and deflazacort, also known as
Emflaza. Mechanisms by which these corticosteroids ameliorate muscular dystrophy
symptoms are not completely understood. However, it is known that prednisone acts in
an anti-inflammatory way to increase skeletal muscle force. Deflazacort functions to
regenerate and differentiate muscle cells.16 As of 2017, deflazacort was FDA-approved in
patients over the age of 5 with DMD, making it the second drug to be approved for
treatment
Orthopedic surgery is often recommended in managing DMD or BMD. Special
consideration must be given to those individuals who undergo surgery as they are at an
increased risk for complications related to lung and cardiac function. In order to maintain
cardiac function, lung function must be maintained as well. Appropriately functioning
lungs reduce respiratory complications as well as reduced stress on the heart.1
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1.5 New treatments
Several therapeutic modalities are being investigated as potential treatments for
patients with muscular dystrophy. Exon-skipping is one potential therapy for muscular
dystrophy patients. Data suggests that up to 80% of DMD could be amenable to exonskipping therapies. Currently in clinical trials, these drugs allow for skipping of mutated
exons in the pre-mRNA to produce a more truncated form of dystrophin and minimize
the effects of the mutation.16 The only FDA-approved exon-skipping drug, eteplirsen,
functions in skipping of exon 51, in which 13% of DMD cases will have a mutation.
Drugs designed for skipping of exons 44, 52, 50, 43, 55, 8 and 35 are currently in
preclinical trials.
Gene therapy, another potential treatment, uses a virus to deliver a functioning
dystrophin gene to cardiac and skeletal muscle cells in order to produce functioning
dystrophin protein. Because of its large size, the dystrophin gene is unable to fit inside a
traditionally used adeno-associated virus (AAV). Thus, a truncated dystrophin gene is
created so as to produce a Becker-like phenotype in the receiving individual. However,
the current challenge includes an adverse immune response from the host.16 Several gene
therapy trials are ongoing for DMD. Notably, in January of 2018, Dr. Mendell and his
team at Nationwide Children’s Hospital, delivered the first dose using a systemic
microdystrophin gene therapy. Gene therapy promises to be a potential avenue for
muscular dystrophy treatment.
Gene editing has also recently surfaced. One specific genome editing tool,
CRISPR/Cas9, provides much potential for curative muscular dystrophy treatment.
CRISPR/Cas 9 makes use of a guide RNA to target a specific location in the genome and
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allows for insertion of a functioning dystrophin gene due to naturally-occurring DNA
repair mechanisms. Due to potential off-target effects as well as ethical dilemmas
surrounding the editing of the human genome, CRIPR/Cas9 is still in the pre-clinical
phase of development.16
Currently in clinical trials, stem cell therapy offers the potential for stem cells
which are able to differentiate into any cell type, to regenerate damaged muscle cells in
muscular dystrophy patients.16
1.6 Health risks in carriers of DBMD
Because muscular dystrophy is caused by a mutation on the X chromosome,
males are generally affected while females are carriers. According to Davie and Emery,17
one third of muscular dystrophy cases are caused by a de novo mutation, and the
remaining two-thirds of cases are inherited from a mother who is a carrier. One study18 of
mothers of sons with muscular dystrophy found the carrier frequency for DMD to be 58%
and the carrier frequency of BMD to be about 90%. Importantly, carriers of DMD and
BMD are at increased risk for specific health concerns.
Penetrance of symptoms is variable in female carriers, and the spectrum of
symptoms is wide. Carriers of DMD are generally more severely affected than carriers of
BMD.19 One study20 determined that up to 7.8% of female carriers are symptomatic with
muscle wasting, myalgia, or muscle cramps. These symptoms had a variable onset
between the ages of 2 and 47 years old. While some carriers exhibited a severe DMD-like
phenotype, others had adult-onset, less severe symptoms.
A study done in the Netherlands by Hoogerwaard et al.7 similarly found that 19%
of DMD female carriers and 16% of BMD female carriers exhibited muscle weakness.
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When cardiac abnormalities were taken into consideration, 22% of carriers exhibited
some symptoms of muscular dystrophy.
A possible explanation for selective female carriers experiencing symptoms could
be due to skewed X-inactivation (XCI). XCI is the process by which females undergo
dosage equalization of the X chromosome. Most females in the general population have a
random pattern of inactivation and thus are mosaic for maternal and paternal X
chromosomes. A non-random XCI pattern could be one explanation for a manifesting
carrier and may even explain age of onset of symptoms as well as severity. However,
there is still a lack of absolute correlation between a muscular dystrophy phenotype in
female carriers and non-random XCI. In fact, Soltanzadeh et al.19 found in their study of
13 manifesting carriers that only five carriers exhibited nonrandom X-inactivation (38%)
which is consistent with other reports suggesting that skewed XCI cannot be the only
explanation for symptoms in manifesting carriers. More research is needed in this area to
determine the impact of X-inactivation on manifesting female carriers.21,22 Genetic
modifiers may be another factor influencing the manifestation of symptoms in carriers.
Genetic modifiers in DMD have been shown to affect age of onset of symptoms, affected
muscle groups, disease progression, and disease severity.23
1.7 Cardiac risk in carriers of DBMD
Most female carriers do not show any outward symptoms of muscular dystrophy.
However, carriers may exhibit a wide range of cardiac abnormalities ranging from mild
findings on echocardiogram to hypertrophic abnormalities, left ventricular dilation
(which can be considered the precursor to dilated cardiomyopathy), and dilated
cardiomyopathies.24,25 These cardiac issues pose serious health threats to carriers and in
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some cases require a transplant or can even result in death.26 Approximately 60% of
DMD and BMD carriers have cardiac abnormalities25 with one study27 finding dilated
cardiomyopathies in approximately 10.9% of carriers. Dilated cardiomyopathies have the
potential to develop heart failure—requiring heart transplantation. Another study7 of 129
Dutch carriers found that 8% of carriers of DMD displayed dilated cardiomyopathy with
an additional 18% of both DMD and BMD carriers presenting with dilation of the left
ventricle on echocardiogram and no presenting muscle weakness. Soltanzadeh and
colleagues19 determined in a study of 13 manifesting carriers that 38% exhibited
decreased systolic function on echocardiogram. In a study24 of 36 carriers utilizing
cardiac magnetic resonance imaging (MRI), myocardial damage and fibrosis were
present in 44% of carriers. Yet another study27 of 197 female carriers found that
preclinical or clinically-detected myocardial anomalies were found in 84.3% of cases of
DMD and BMD carriers. Furthermore, the significance of cardiac involvement increased
with age with 54.5% of carriers aged 5 to 16 years old experiencing cardiac involvement
and 90.2% in those older than 16 years. Significant cardiac disease is not common in
those under 16 years of age. Cardiomyopathies tend to develop in the fourth or fifth
decade of life and progress slowly.21
One study conducted by McCaffrey et al.28 found that carriers showed
abnormalities on cardiac MRI 3-33% of the time depending upon the definition of
cardiomyopathy and different measurements such as left ventricular fractional shortening
and left ventricular ejection fraction. Based on echocardiogram, they found that 7-13%
exhibited significant systolic dysfunction. They additionally found that cardiomyopathy
in all cases was not associated with mutation type, DMD vs. BMD phenotype, creatine
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kinase level, the presence of muscle symptoms, or even age. All of the subjects in this
study were asymptomatic—reporting no intolerance to exercise, breathlessness,
arrhythmias, or cardiac failure.
1.8 Surveillance recommendations for DBMD carriers
According to the American Academy of Pediatrics Section on Cardiology and
Cardiac Surgery published in 2005,1 carriers should be made aware of their risk for
cardiomyopathy and educated on the signs of heart failure. Additionally, they should be
referred to a cardiac specialist for a complete cardiac evaluation in late adolescence or
early adulthood—including a history and physical examination, electrocardiogram
(EKG), and a transthoracic echocardiogram. Re-evaluation with a cardiologist should
occur every five years beginning between the ages of 25 and 30. Treatment of
cardiomyopathy in carriers is similar to treatment for individuals with DBMD as outlined
in the American Academy of Pediatrics (AAP) guidelines.
While echocardiogram is the current screening standard for cardiomyopathy,
cardiac MRI is increasingly becoming the preferred method of screening used by
cardiologists. Cardiac MRI, also known as cardiovascular magnetic resonance (CMR) is
a tool used to detect myocardial fibrosis, a sign of cardiomyopathy. The use of cardiac
MRI could detect subtle pathologies of the myocardium in the event of a normal
echocardiograph evaluation. Cardiac MRI is increasingly becoming a preferred screening
tool to identify patients at increased risk of cardiac abnormalities and to identify those
patients that should begin treatment so as to delay the progression of the cardiomyopathy.
A study conducted by Mavrogeni et al.29 determined that up to 66% of carriers will
present with an abnormal finding detected by CMR whereas only 17% of those carriers
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would present with an abnormal echocardiogram.24 A recent study30 performed on a
small group of 15 carriers found that all DMD carriers exhibited cardiac abnormalities
when screened with cardiac MRI.
Treatment for cardiomyopathy in carriers is similar to the treatment of
cardiomyopathy in patients with DBMD.1 Guidelines for management of patients with
cardiomyopathies recommend implementation of drugs such as angiotensin converting
enzyme inhibitors or beta-blockers.31 ACE inhibitors prevent the conversion of
angiotensin I to angiotensin II which ultimately lowers artery resistance, increases venous
capacity, increases cardiac output and index, increases stroke volume, and increases
natriuresis. Beta-blockers bind to beta-adrenoceptors in order to block norepinephrine
and epinephrine from binding. This reduces stimulation of heart rate, contractility,
electrical conduction, and relaxation rate.32
1.9 Adherence to surveillance recommendations among carriers
According to recent research, female carriers of DMD or BMD may not be
adhering to the recommendations outlined by the AAP. One study33 found that of 833
carriers, 35.6% of them had never had a cardiac evaluation despite knowing their carrier
status. A similar study26 of 137 known carriers and 45 of unknown status found that only
45.5% of confirmed female carriers had had an echocardiogram in the last five years with
21% of them never having had an echocardiogram. While known carriers were twice as
likely to have had an echocardiogram in the last five years than those of unknown status,
having a son recently diagnosed with muscular dystrophy had no significant effect on
whether or not an echocardiogram was performed recently.
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Many factors could contribute to a lack of adherence to the AAP
recommendations in carriers. According to Bobo et al.33 69% of female carriers stated
that their healthcare providers were aware that they were a carrier of DBMD. Those
carriers that had an informed healthcare provider were significantly more likely to have
had a cardiac evaluation when compared with those women whose healthcare providers
were not aware of their carrier status. This study found that certain factors increased a
carrier’s likelihood of having a heart test including being over the age of 49, having a
female relative with heart disease, having awareness of their cardiomyopathy risk, and
having an informed healthcare provider.
Bobo and colleagues33 also found that cost was a factor that inhibited women
from participating in cardiac surveillance. In addition, having no symptoms of heart
disease, receiving no recommendations from a healthcare provider, having no awareness
of cardiac risks, and having no muscle weakness were all reasons for not pursuing cardiac
screening. This study found that 37.1% of carriers had never heard or read about their
increased risk for cardiomyopathy in the past which suggests that a lack of knowledge of
associated cardiac risk is a potential barrier.
Many carriers of DBMD who are aware of their carrier status do not seem to be
following self-care recommendations regarding cardiac surveillance as detailed by the
AAP even though up to one in ten may experience overt cardiac failure.34 Various factors
may contribute to challenges experienced by this population in obtaining appropriate
cardiac surveillance including:
1) Carriers may have received inadequate and insufficient education at the time
that they were informed of their carrier status.
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2) If the individual’s carrier status was revealed at the same time period in which
her son was diagnosed with muscular dystrophy, her own diagnosis could have
been overshadowed by the information of her son’s diagnosis.
3) Carriers may refrain from cardiac surveillance because of a perceived low risk
of developing a cardiomyopathy. This may be because she is unaware of the
severity of cardiomyopathies, because she has other female carrier relatives who
have not developed symptoms or are also not adhering to the recommendations,
or again, because of a lack of education.
4) Some carriers may have limited access to healthcare. Socioeconomic status,
accessibility to a vehicle, time it takes to get to the appointment, availability of the
cardiologist, and other healthcare disparities potentially factor into healthcare
access.
5) Caring for a son with muscular dystrophy has taken precedence over the
carrier’s own health. Studies have shown that those who take the role of a
caregiver experience stress, distress, high caregiving demands, and are more
likely to have psychological effects related to the caregiving.35
Hypothesis
Various barriers may inhibit female carriers of DBMD from obtaining appropriate
cardiac surveillance. Lack of education, perceived low cardiomyopathy risk, lack of
accessibility to a cardiologist, burden of being a caregiver for an affected son or sons, or a
combination of factors may contribute to poor adherence to the AAP recommendations in
female carriers. In order to identify the specific barriers that female carriers experience,
this study will explore three specific aims:
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1) Assess the experience of female carriers at their initial discovery of their carrier
status.
2) Determine the specific cardiac care practices that female carriers are following
or not following.
3) Identify perceived challenges and barriers to appropriate cardiac care.
By making an effort to understand the needs of this patient population, healthcare
professionals may be able to better address specific concerns that this population is facing
in obtaining appropriate cardiac self-care. This presents as an opportunity for genetic
counselors to become more aware of the needs of this population themselves but also to
raise awareness and to advocate for this population that may be underserved. Through
one-on-one interviews, this study aims to evaluate the barriers to self-care that carriers of
DMD or BMD are experiencing. This is primarily an exploratory study, and its goal is to
provide insight into a population to highlight unique areas of concern or unmet needs that
could be addressed by genetic counselors and other healthcare providers.
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CHAPTER 2:
ASSESSING THE BARRIERS TO CARDIAC CARE IN CARRIERS OF
DUCHENNE AND BECKER MUSCULAR DYSTROPHY1
2.1 Abstract
Purpose: Duchenne and Becker muscular dystrophy (DBMD) are X-linked conditions
causing progressive muscle weakness, respiratory insufficiency, and cardiomyopathy in
affected males. Approximately two-thirds of women who have a son with DBMD are
heterozygote carriers of the condition. Carriers typically do not manifest muscular
symptoms but up to 60%25 are at risk for cardiac abnormalities with one study27 finding
10% of DBMD carriers with development of dilated cardiomyopathy. The American
Academy of Pediatrics (AAP) recommends that carriers of DBMD receive a complete
cardiac evaluation by a cardiologist between age 25 and 30 that includes echocardiogram
and electrocardiogram with re-evaluation every five years. Recent studies33 suggest as
many as 35.6% of carriers are not adhering to that five-year recommendation despite
having knowledge of their carrier status. Limited research has been conducted into the
barriers that carriers of DBMD face in accessing recommended cardiac screening.
Methods: Participants completed a short questionnaire to identify carriers who were and
were not following the AAP recommendations. Semi-structured telephone interviews
were offered to 11 carriers of DBMD who in the last five years had not seen a

1

Eekhoff, L., Edwards, J., Martin, A., & Prijoles, E. To be submitted to Journal of Family Practice
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cardiologist, had an echocardiogram, had an EKG, or a combination to determine the
perceived challenges that carriers face in obtaining appropriate cardiac care.
Results: Most carriers surveyed (71.7%, 43/60) reported adherence to appropriate cardiac
care while 28.3% (17/60) of carriers in our study did not receive appropriate care. From
the participants interviewed (11/17), seven major themes emerged as barriers to the
receipt of cardiac care. These included a perception amongst carriers that healthcare
providers lacked awareness of cardiac risks and associated recommendations. Carriers
perceived a decreased risk for cardiac complications due to a perceived healthy lifestyle
or lack of family history of cardiac events. Some carriers experienced a lack of
information-sharing among family members. Carriers tended to place the healthcare
needs of family members above their own. Carriers believed conversations about carrier
status should begin at a younger age.
Conclusions: This study called attention to the barriers of obtaining appropriate cardiac
care among this population. Increased awareness and advocacy for this unique group is
essential with the goal that all members of this population receive the cardiac care that
they need.
2.2 Introduction
Duchenne and Becker muscular dystrophy (DMD and BMD) are neuromuscular
disorders known as dystrophinopathies, caused by X-linked mutations within the
dystrophin gene located at chromosome Xp21.1.1 Duchenne muscular dystrophy is the
most severe of the childhood muscular dystrophies. Symptoms in childhood begin with
muscle weakness and wasting that renders affected individuals non-ambulatory
commonly by the age of 12.1,9 Dilated cardiomyopathies and arrhythmias typically are
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found in individuals with DMD. In fact, death often occurs in the mid-20s due to cardiac
events.14
Becker muscular dystrophy is generally a less severe form of muscular dystrophy
in which muscle weakness presents later in life.14 Affected individuals remain ambulatory
longer and death occurs later—into the fourth and fifth decades.
Two-thirds of DBMD are due to pathogenic variants on the X chromosome
inherited from a female carrier.17 Carriers typically do not present with symptoms of
muscle wasting; however, they are at increased risk for significant cardiac events
including hypertrophic involvement, left ventricular dilation, and
cardiomyopathy.19,20,24,25,27 One group34 estimates that approximately 10% of DBMD
carriers will develop overt cardiac failure.
Cardiac disease poses serious health threats to carriers and in some cases requires
a transplant or can result in death.26 In a study of 129 carriers, Hoogerward et al.25 found
that approximately 60% of muscular dystrophy carriers experienced cardiac
abnormalities detected by echocardiogram. Of these, 8% of cardiac abnormalities were
dilated cardiomyopathies. In a study24 of 36 carriers utilizing cardiac MRI, myocardial
damage and fibrosis were detected in 44% of carriers. Yet another study27 of 197 female
carriers found that preclinical or clinically-detected myocardial anomalies were found in
84.3% of cases of DMD and BMD carriers. Furthermore, the significance of preclinical
or clinically evident cardiac involvement increased with age with 54.5% of carriers aged
5 to 16 years old experiencing cardiac involvement and 90.2% in those older than 16
years. Thus, the possibility of cardiac events in carriers of DBMD is evident, and the
cardiac care needs of this population must be consistently addressed.
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The American Academy of Pediatrics (AAP) recommends carriers of DBMD be
referred to a cardiac specialist for a complete cardiac evaluation at the time of diagnosis.
Subsequent evaluations should occur every five years beginning between the ages of 25
and 30. These evaluations should include EKG, echocardiogram, and consideration for a
cardiac MRI.1 Evidence suggests that carriers of muscular dystrophy may not be adhering
to the AAP recommendations. Bobo et al.33 found that of 833 carriers, 35.6% had never
had an echocardiogram despite being aware of their carrier status. A similar study26 of
182 women published in 2016 found that only 45.5% of confirmed carriers had had an
echocardiogram in the past five years.
To identify the specific barriers to receiving cardiac care that carriers of DBMD
experience, this study aimed to: 1) Determine the specific cardiac care practices that
carriers are and are not following 2) Identify perceived challenges and barriers to
appropriate cardiac care in this unique population at risk for cardiac disease.
2.3 Materials and Methods
Participants
Women over the age of 18 were eligible to participate in this study if they had a
family history indicating their carrier status or if they had completed genetic testing
confirming they were a carrier of DBMD. Carrier status was based upon self-reported
data. The University of South Carolina Institutional Review Board reviewed the protocol
and designated it as exempt from review.
Instrumentation
A 10-item questionnaire was distributed via a web link (See Appendix A) that
was sent in an email to over 500 registrants of DuchenneConnect, an online registry for
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individuals with Duchenne and Becker muscular dystrophy and carrier females in the
United States. The study information and questionnaire link were emailed twice. These
were first distributed to registered manifesting carriers or confirmed carriers and then to
DBMD registrants who reported that their mother was a carrier. The questionnaire
assessed: a) Knowledge and confirmation of the participant’s own carrier status and b)
Personal screening history for cardiac risks. Additionally, the participants could provide
contact information if they wished to be contacted for a semi-structured telephone
interview. Eligible for the interview were those participants who had not had an EKG,
echocardiogram or cardiac MRI in the past five years, or seen a cardiologist in the past
five years.
Telephone interviews included questions about participants’ initial discovery of
their carrier status, current healthcare services received, and challenges they perceived in
obtaining appropriate cardiac care (see Appendix B for interview questions). All
interviews were recorded using either VoiceRecorder or RecordPad Sound Recorder and
were saved on the researcher’s private computer under password protection.
Data analysis
The researcher transcribed all interviews. All transcripts were analyzed for themes
using grounded theory data analysis. Interviews were separately reviewed and coded
independently by the author and a research assistant. Kappa coefficient was calculated at
0.68. Quantitative data was described by counting response types and through descriptive
statistics (percentages and means). All identified themes and representative quotes can be
found in Appendix C.
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2.4 Results
Sixty individuals registered with DuchenneConnect completed the online
questionnaire. Forty-three individuals (43/60, 71.7%) received appropriate cardiac care as
evidenced by self-reported receipt of an echocardiogram, EKG, and a visit with a
cardiologist within the past five years. Seventeen individuals (17/60, 28.3%) either had
not been seen by a cardiologist, had an EKG, or had an echocardiogram in the past five
years. Three of these individuals did not provide contact information for a telephone
interview. An additional three individuals were unable to be contacted for an interview.
Telephone interviews were conducted with eleven individuals. Interviews lasted between
22 and 51 minutes (median 28 minutes).
Many carriers interviewed (9/11) were Caucasian. The majority of carriers
worked outside the home (7/11). Education level ranged from completion of high school
to doctorate level, master’s degree, and law degree. The majority (9/11) lived in an urban
area. Figure 2.1 indicates states represented by participants interviewed. The two
participants from Texas were not related to one another. No participants stated relation to
any other participants interviewed.
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Figure 2.1 States represented by carriers interviewed (n=11). Two carriers
interviewed were from Texas.
Most carriers (10/11) had had confirmatory genetic testing with one individual
determined to be an obligate carrier based on the pattern of inheritance from her family
history.
Much variability existed in the specific cardiac screens that each participant had
and had not undertaken. Figure 2.2 represents the specific screenings that the carriers
interviewed completed using the recommended five-year interval outlined by the AAP.
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Figure 2.2 Adherence to cardiac screenings among carriers
interviewed based upon AAP recommendations (n=11)

Participants interviewed ranged in age from 28 to 70 with a mean age of 40 years.
Figure 2.3 demonstrates the age at which each participant discovered they were a carrier
compared to their age at the time of the interview. An average of 12 years elapsed since
participants’ discovery of carrier status and the time interviewed representing the amount
of time they had not been receiving appropriate cardiac screening.
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Figure 2.3 Amount of time between participants’ discovery of carrier status and age at
present (n=11)

Many carriers (8/11) had a living son with muscular dystrophy, and most of those
individuals (6/8) reported discovering their carrier status while their son was diagnosed
with muscular dystrophy. Most carriers (7/10) recalled meeting with a genetic counselor
who explained the testing and the results; however, only 5/10 recalled the associated
cardiac risks being discussed with them. Notably, even though all carriers interviewed
had a primary care physician who was aware of their carrier status, the majority (8/11)
were unfamiliar with the AAP recommendations for cardiac screening. Additional
background information about the participants interviewed can be viewed in Table 2.1.
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Table 2.1 Background information of carriers interviewed (n=11)

Question
Do you have a son with muscular
dystrophy?
Did you discover your carrier status
upon your son's diagnosis?
Do your son's doctors ever discuss
your carrier status?
Were you referred for a complete
cardiac evaluation at the time of
diagnosis of carrier status?
Are you aware of the AAP
recommendations?
Is your PCP aware of your carrier
status?

Not
applicable

Yes

No

8

3

6

2

3

2

5

4

5

6

3

8

11

0

Several themes emerged from analysis of the interview transcripts. Each theme is
illustrated by verbatim quotes from the interview transcripts.
Theme 1: Carriers experienced a lack of awareness regarding cardiac risks among
healthcare providers.
This most common theme identified was discussed by all carriers interviewed.
Carriers reported a lack of understanding among primary healthcare physicians and
cardiologists about muscular dystrophy, carriers of muscular dystrophy, and associated
cardiac risks. Carriers most often cited among cardiologists that there was an
unfamiliarity with the necessity of cardiac screening for carriers. Carriers often felt like
they were responsible for educating their healthcare providers about symptoms associated
with being a carrier and about the recommended screenings they needed.
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…the PCP was like, “Well why are you here?” type of thing. And
so…basically the PCPs have no clue about, you know, Duchenne or any of
those muscular dystrophy types.

I saw a cardiologist here locally…he had no idea why I was there. It was
completely useless. Giant waste of time.
Additionally, some healthcare providers may not be familiar with the AAP
recommendations. Some patients (6/11) reported that upon discovery of their carrier
status, they were not referred by their healthcare provider for an initial cardiac evaluation
as per the AAP recommendations. Many reported receiving misinformation regarding the
necessity of frequent examinations.
After I had my first one [cardiac evaluation], they told me, “Your heart is
healthy…There’s no reason for you to ever come back.”

So I took my daughter to see the cardiologist, and the cardiologist
dismissed my concerns and said, “You’re done. Graduate.” And that was
that.
Theme 2: Carriers were responsible for educating themselves about risks associated
with being a carrier; carriers were their own advocates.
Despite all carriers reporting that their primary healthcare physician (PCP) was
aware of their carrier status (11/11), the majority reported that their PCP did not discuss
cardiac risks or remind them to have cardiac screenings. Often this left carriers on their
own and forced them to seek out appropriate care independently.
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You’re kind of left with it on your own. I had to take initiative with
organizing cardiology appointments. And my doctor won’t get on me to
remind me to do it because he has no real expertise in that area. When I
had my Holter monitor test, I was telling everything to my doctor about my
carrier status, and he was on the computer looking it up.

I do have to be the one that asks for these tests. Like [my PCP]…is not like
monitoring it. It’s more if I bring it up.
Carriers reported often turning to sources outside healthcare professionals such as
the internet or other carriers to receive information about their carrier status. Many
acknowledged a frustration with the lack of resources and information and a desire for a
more easily accessible and reliable source for information for carriers.
Just like looking it up and just hearing from other people that are carriers
as well and not too much detail just kind of word of mouth from what
everyone else was saying. So there’s not too much on the internet about it,
so just from hearing from other…moms that are carriers as well.
Carriers reported the added challenge of working with a healthcare professional
who is unaware of a condition, its associated risks, and recommendations for screening.
They reported the burden and difficulty of being a self-advocate for their condition.
I think also you kind of need that permission to do [cardiac screenings].
You know like if your doctor’s saying you have to go do X, Y, Z you’re
going to do it. It’s a lot harder to go out of your way to say, “You know
what, I need to do. I need a screening.”
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Theme 3: Carriers were frustrated with the misinformation they had received
regarding cardiac risks and wished to be educated about associated risks.
Carriers reported being unaware of specific risks and recommendations associated
with their carrier status. The majority were unfamiliar with the AAP recommendations
(8/11). For some, this lack of personal awareness was frustrating.
…it really bothers me. [The AAP recommendations] is something I should
have known or been doing all along…maybe it would have answered some
questions I had or could explain what was going on with me…or knowing
that it was something if I could have caught ahead of time maybe I could
have done something about it.
Carriers reported a desire for more information specifically about symptoms to be
aware of, the nuances of the different heart screening tests, and what a risk for
cardiomyopathy truly means. Despite the desire to be educated about cardiac risks, many
carriers discussed the difficulty in obtaining information about carriers of DBMD. They
reported obtaining information regarding cardiac risks from a variety of sources including
the internet, family members, or other carriers. Oftentimes, this information was not
accurate and was presented that carrier status only affects family planning decisions and
future pregnancies.
I just also remember like it being communicated to me from [my father]
that it doesn’t affect that many carriers and it’s not something you need to
worry about until you’re older.
Misinformation included being unaware of the benefit of a cardiac evaluation, a
misunderstanding of the mechanism of cardiac risks, and the exact risks associated with
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being a carrier. In some cases, this misinformation resulted in a lack of concern for
associated cardiac risks.
I don’t really feel like I’m very educated on…what to expect as a carrier,
what to be mindful of.
Theme 4: Carriers were unconcerned about cardiac risks due to perceived healthy
lifestyles or a lack of a family history of cardiac events.
Many participants pointed to a lack of family history of cardiac events in other
family members who were carriers as evidence of their lack of concern for cardiac risks.
Even those who had a history of cardiac events were unconcerned because no healthcare
provider had ever associated muscular dystrophy with the history of cardiac events.
I also talked to my mom and she said well our family history—which we
know quite well—we don’t seem to have that cardiac complication…her
mom died of cancer at an advanced age. Her mom who was the sister of
the…great-great uncles who would’ve had Duchenne, she lived deep into
her nineties, had no cardiac trouble. Her mom didn’t have a cardiac
problem either so we figured we were ok to not really bother.
A perceived active and healthy lifestyle including frequent exercise and eating a
healthy diet was also cited as a reason for less concern for cardiac complications in
carriers.
I ride my bicycle. I go out on long hikes…I you know don’t really have
any…problems.
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Theme 5: Some carriers experienced a lack of openness and information-sharing
with other family members who were also carriers.
When asked about the amount of information-sharing amongst other carriers in
the family, some participants (4/9) reported that they do not discuss their carrier status or
cardiac care with other family members, specifically family members who are or are at
risk to be carriers of DBMD. Many reported being unsure as to whether those family
members received the recommended cardiac screenings. Some reported that the lack of
openness was due to feelings of guilt associated with passing on the mutation within the
family.
It’s kind of a touchy subject, an upsetting subject, because if [my mother]
ever found out she was the cause of everything, it would be very upsetting.
Other reasons for a lack of openness among family members included religious
beliefs and a lack of apparent symptoms amongst other family members that would
otherwise be cause for concern.
There’s this strange notion that…amongst their family that…God had
punished them somehow by giving them this..it’s just like something they
just never talk about. I think it’s just too painful for my mom’s family so
I’m a little nervous or shy about bringing it up.
Theme 6: Carriers tended to put the needs of their family members before their own
healthcare needs.
The majority of carriers interviewed (8/11) reported having a living son with
muscular dystrophy. For some participants (3/11), this meant staying in the home fulltime to provide care for their son. They reported that caregiving for a child with medical
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needs takes a significant amount of time and energy. Often their own healthcare needs
took less precedence to the needs of their children.
I’m the last person to think of myself. You know there’s so many other
things I have to do and the life schedule of living with kids with special
needs is hardcore. It is…not easy to find the time to breathe let alone the
time to say I should take care of myself…

I’m usually seeing the doctor like when I’m at the end of the rope.
Theme 7: Carriers believed conversations about carrier status and associated risks
should begin at an earlier age.
Participants believed that conversations about carriers and risks should begin at a
young age, and information should include more than reproductive-planning and
recurrence risks. Some carriers (5/11) recalled at their initial diagnosis that the
information delivered was focused on reproductive recurrence risk with little mention of
the potential physical symptoms associated with being a carrier.
And it would totally change lives sometimes for the better, sometimes for
the worse, but for very different if these girls understood from the very
young age…
Carriers acknowledged that often the healthcare needs of those affected with
muscular dystrophy became a priority of healthcare professionals and caregivers so that
carriers felt more or less forgotten.
Carriers matter and carriers have symptoms…it’s not necessarily the
muscles, and our life expectancies may indeed be comparable to other
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people, but we have some serious needs that would help our lives so much
to be addressed.
2.5 Discussion
This interview-based qualitative study explored the barriers to adherence to the
AAP recommendations for cardiac screening amongst carriers of Duchenne and Becker
muscular dystrophy. Our screening questionnaire identified that 71.7% (43/60) carriers
received appropriate cardiac screening as outlined by the AAP recommendations. This
number is higher than was found in two previous studies of carriers of DBMD; one
study33 determined that 64.4% of known carriers had ever had a cardiac evaluation, and a
similar study26 found that 45.5% of carriers surveyed had had an echocardiogram in the
past five years. The high proportion of carriers in our study that were adhering to the
AAP recommendations indicated that the majority of carriers within the
DuchenneConnect population are informed of the recommendations and are being
appropriately screened by cardiologists. This high percentage may be due to a number of
factors. The homogenous group of study participants taken from the DuchenneConnect
Registry may have increased access to educational materials through the website and
email service provided by the Registry and Parent Project Muscular Dystrophy (PPMD),
the advocacy organization that funds the Registry. Both the DuchenneConnect Registry
and PPMD may also provide a platform for increased support and accountability from
other members to stay up-to-date on cardiac screenings. Additional research is needed to
understand the reasons why and how this population is receiving information and is
motivated to adhere to the recommendations.
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Despite the finding that the majority of carriers surveyed received appropriate
cardiac care, the focus of this study was on the 28.3% (17/60) who did not adhere to the
AAP recommendations. The lack of adherence to the recommendations amongst the
minority poses a serious healthcare risk to these carriers. Those risks include an increased
likelihood to develop cardiac abnormalities including cardiomyopathy which could result
in premature death if left undetected and untreated. Previous research26,33 has found that
possible reasons for a lack of adherence to the AAP recommendations among DBMD
carriers may include factors like lack of personal awareness of cardiac risk, having an
uninformed healthcare provider, knowledge of carrier status, and cost.
A number of barriers to accessing cardiac care were identified from the interviews
with the eleven carriers in this study. The major theme recognized was a perceived lack
of awareness of associated cardiac risks and screening recommendations displayed by
cardiologists, primary care physicians, and other healthcare providers. Carriers
experienced frustration with healthcare professionals who displayed lack of awareness,
resources, and information for carriers. More education efforts may be needed to ensure
that healthcare providers are aware of the increased risk for cardiac abnormalities in
carriers, of the AAP recommendations, and of appropriate sources for referral.
Carriers were identified as self-advocates and were responsible for self-education
regarding their carrier status and associated risks. Frustration with misinformation
received and with lack of accessible information available to them was recurrent. A
thorough and clear explanation of DBMD carrier status including potential symptoms and
risks associated with being a carrier is of utmost importance upon initial diagnosis. Initial
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counseling about the diagnosis should encompass cardiac care for carriers in addition to
reproductive risks.
Healthcare providers are in a position to point carriers to appropriate sources of
information so that they are informed of cardiac risks and are empowered to seek
appropriate care. Many healthcare providers including cardiologists, neurologists,
pulmonologists, nutritionists, genetic counselors, and many more specialties are involved
in the care of a child with muscular dystrophy. A responsibility of healthcare providers
involved on this multidisciplinary team in a muscular dystrophy clinic involves
recognizing not only the needs of the child affected with Duchenne or Becker muscular
dystrophy, but also his mother who is a potential carrier. A unique opportunity exists for
healthcare providers to share appropriate resources and information for mothers who are
carriers. This may include educational pamphlets or reputable internet sources. One such
online resource is PPMD, (www.parentprojectmd.org) and their DuchenneConnect
Registry (www.duchenneconnect.org). The PPMD website provides information on care,
research, and advocacy including detailed information for DBMD carriers. DBMD
carriers are also encouraged to join the DuchenneConnect Registry.
A lack of family history of cardiac events and a perceived healthy lifestyle may
also act as a barrier to receiving cardiac care for some carriers. It is unclear the extent that
cardiac abnormalities affect carriers in different families. The lack of family history of
cardiac events should not be considered evidence of a decreased risk for an abnormality.
Even carriers without a family history of cardiac events among carriers should adhere to
the AAP recommendations. The AAP recommends that all carriers require periodic
cardiac screening with the rationale that the risk for developing cardiac disease is present

33

“irrespective of skeletal muscle disease.”1 Inherited cardiomyopathy cannot be prevented;
however, carriers should be encouraged to follow healthy lifestyle practices such as
frequent exercise and a balanced, heart-healthy diet.
Lack of communication within a family amongst carriers may more easily foster a
lack of adherence to AAP recommendations. Previous research has identified that having
a female family member with heart disease increased the likelihood of personal receipt of
a cardiac test.33 Without other family members as a resource for information and
accountability, it is important that carriers receive appropriate and accurate information
from their healthcare providers regarding necessity and timing of cardiac screenings.
Genetic counselors are equipped through their specific training to navigate the difficulty
of closed familial relationships and feelings of guilt within a family as well as to address
information regarding risks to carriers, the genetic mechanism of disease, and recurrence
risks. Recognition of need and identification of referrals to other specialists like genetic
counselors may be appropriate in the care of carriers of DBMD.
Carriers may put the healthcare needs of their sons with muscular dystrophy over
their own healthcare needs. This is not a unique finding to this population. In fact,
previous studies36 have shown that caregivers of children with a chronic condition have a
significantly lower health-related quality of life which includes areas such as cognitive
functioning, sleep, social functioning, daily activities, vitality, and positive and
depressive emotions than parents who are not caregivers of a chronically-ill child.
Healthcare professionals have the responsibility to emphasize to carriers the importance
of adherence to the cardiac care recommendations of the AAP. Beyond that, healthcare
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professionals must recognize the burden of caregiving experienced by an individual and
should be prepared to offer support.
Carriers desired that conversations about their carrier status begin at an earlier age
and include more than information regarding reproductive recurrence risk. Genetic
testing of a minor may act as a barrier to determination of carrier status until a potential
carrier reaches the age of 18; however, many healthcare providers and families are now
open to carrier testing of children under the age of 18. Communication within the family
unit about carriers and their associated risks should be encouraged by healthcare
providers.
This study offered insight into the challenges that carriers of DBMD faced in
obtaining recommended cardiac care. As indicated by the carriers interviewed in this
study, the most significant barrier to obtaining cardiac care was a perceived lack of
education and awareness experienced among healthcare providers. The goal of this study
was to call attention to the needs of this population and to provide education for those
medical professionals who serve them. We hope that this study will be valuable to the
healthcare community and will prompt personal evaluation, and a potential adjustment of
practice, of each individual provider’s interaction with members of this unique
population. Increased awareness and advocacy efforts are necessary until the entire
group, that is carriers of Duchenne and Becker muscular dystrophy, is able to receive
appropriate cardiac care.
Limitations
Study participants were registrants of DuchenneConnect and thus this study
surveyed a small proportion of carriers of DBMD who are actively seeking information
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through this organization. Sixty carriers completed the survey of the over five hundred
registrants to whom the survey was sent. The majority of our participants were Caucasian
and highly educated. Findings from this study were specific to participants interviewed
and cannot be generalized to the larger population of carriers of muscular dystrophy.
Future research
Future research may include an exploration of the different sources of information
provided to carriers and their efficacy in prompting cardiac screening. Additionally,
future research should target a larger, more heterogenous group of carriers to determine
more accurately the specific barriers to obtaining appropriate cardiac care experienced.
Further, more research is warranted into the significant majority of carriers identified in
this study that are receiving appropriate cardiac care. This may include more in-depth
research into the specific information individuals have received regarding carrier status,
associated risks, and patient resources.
Conclusions
A significant number of DBMD carriers received appropriate cardiac care based
upon the AAP recommendations. A perceived lack of education and awareness among
healthcare providers was a barrier most often reported by carriers who were not receiving
appropriate cardiac care. Increased educational and awareness efforts are needed among
healthcare providers and carriers about DBMD to promote increased adherence to cardiac
screening among all DBMD carriers.
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CHAPTER 3:
CONCLUSIONS
Carriers of Duchenne and Becker muscular dystrophy are at increased risk for
cardiac complications including cardiomyopathy. Previous research has found that some
carriers may not be adhering to the AAP recommendations that state that every five
years, carriers should be seen by a cardiologist and receive an EKG and echocardiogram.
This study found that 71.7% of carriers surveyed received appropriate cardiac
care. Of the 28.3% who did not receive recommended care, several themes were
identified that represented barriers to obtaining appropriate care. The most common
theme discussed was a perceived lack of awareness among healthcare providers and
available resources for carriers.
Healthcare providers including primary care physicians, cardiologists, genetic
counselors, and all those involved in the care of carriers of DBMD have the responsibility
to be well-informed regarding the needs of this population. Carriers as well as healthcare
providers can work together to promote increased awareness and advocacy so as to
ensure the needs of this group are met.

37

REFERENCE LIST
1. American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. (2005).
Cardiovascular health supervision for individuals affected by Duchenne or Becker
muscular dystrophy. Pediatrics, 116(6), 1569–1573.
https://doi.org/10.1542/peds.2005-2448
2. Kamdar, F., & Garry, D. J. (2016). Dystrophin-Deficient Cardiomyopathy. Journal of
the American College of Cardiology, 67(21), 2533–2546.
https://doi.org/10.1016/j.jacc.2016.02.081
3. Sansović, I., Barišić, I., & Dumić, K. (2013). Improved detection of deletions and
duplications in the DMD gene using the multiplex ligation-dependent probe
amplification (MLPA) method. Biochemical Genetics, 51(3–4), 189–201.
https://doi.org/10.1007/s10528-012-9554-9
4. Juan-Mateu, J., Gonzalez-Quereda, L., Rodriguez, M. J., Baena, M., Verdura, E.,
Nascimento, A., … Gallano, P. (2015). DMD Mutations in 576 Dystrophinopathy
Families: A Step Forward in Genotype-Phenotype Correlations. PloS One, 10(8),
e0135189. https://doi.org/10.1371/journal.pone.0135189
5. Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al-Dahhak, R., GastierFoster, J., … Weiss, R. B. (2012). Evidence-based path to newborn screening for
Duchenne muscular dystrophy. Annals of Neurology, 71(3), 304–313.
https://doi.org/10.1002/ana.23528

38

6. Flanigan, K. M., Dunn, D. M., von Niederhausern, A., Soltanzadeh, P., Gappmaier, E.,
Howard, M. T., … Weiss, R. B. (2009). Mutational spectrum of DMD mutations in
dystrophinopathy patients: application of modern diagnostic techniques to a large
cohort. Human Mutation, 30(12), 1657–1666. https://doi.org/10.1002/humu.21114
7. Hoogerwaard, E. M., Bakker, E., Ippel, P. F., Oosterwijk, J. C., Majoor-Krakauer, D.
F., Leschot, N. J., … de Visser, M. (1999). Signs and symptoms of Duchenne
muscular dystrophy and Becker muscular dystrophy among carriers in The
Netherlands: a cohort study. Lancet (London, England), 353(9170), 2116–2119.
8. Noritz, G. H., Murphy, N. A., & Panel, N. S. E. (2013). Motor Delays: Early
Identification and Evaluation. Pediatrics, 131(6), e2016–e2027.
https://doi.org/10.1542/peds.2013-1056
9. Connolly, A. M., Florence, J. M., Cradock, M. M., Malkus, E. C., Schierbecker, J. R.,
Siener, C. A., … MDA DMD Clinical Research Network. (2013). Motor and
cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy:
results from the Muscular Dystrophy Association DMD Clinical Research Network.
Neuromuscular Disorders: NMD, 23(7), 529–539.
https://doi.org/10.1016/j.nmd.2013.04.005
10. Hendriksen, J. G. M., & Vles, J. S. H. (2008). Neuropsychiatric disorders in males
with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity
disorder (ADHD), autism spectrum disorder, and obsessive--compulsive disorder.
Journal of Child Neurology, 23(5), 477–481.
https://doi.org/10.1177/0883073807309775

39

11. Mewton, N., Liu, C. Y., Croisille, P., Bluemke, D., & Lima, J. A. C. (2011).
Assessment of myocardial fibrosis with cardiovascular magnetic resonance. Journal
of the American College of Cardiology, 57(8), 891–903.
12. Tandon, A., Villa, C. R., Hor, K. N., Jefferies, J. L., Gao, Z., Towbin, J. A., …
Taylor, M. D. (2015). Myocardial fibrosis burden predicts left ventricular ejection
fraction and is associated with age and steroid treatment duration in duchenne
muscular dystrophy. Journal of the American Heart Association, 4(4).
https://doi.org/10.1161/JAHA.114.001338
13. Yiu, E. M., & Kornberg, A. J. (2015). Duchenne muscular dystrophy. Journal of
Paediatrics and Child Health, 51(8), 759–764. https://doi.org/10.1111/jpc.12868
14. Flanigan, K. M. (2014). Duchenne and Becker muscular dystrophies. Neurologic
Clinics, 32(3), 671–688, viii. https://doi.org/10.1016/j.ncl.2014.05.002
15. Biggar, W. D., Harris, V. A., Eliasoph, L., & Alman, B. (2006). Long-term benefits
of deflazacort treatment for boys with Duchenne muscular dystrophy in their second
decade. Neuromuscular Disorders: NMD, 16(4), 249–255.
https://doi.org/10.1016/j.nmd.2006.01.010
16. Robinson-Hamm, J. N., & Gersbach, C. A. (2016). Gene therapies that restore
dystrophin expression for the treatment of Duchenne muscular dystrophy. Human
Genetics, 135(9), 1029–1040. https://doi.org/10.1007/s00439-016-1725-z
17. Davie, A. M., & Emery, A. E. (1978). Estimation of proportion of new mutants
among cases of Duchenne muscular dystrophy. Journal of Medical Genetics, 15(5),
339–345.

40

18. Lee, T., Takeshima, Y., Kusunoki, N., Awano, H., Yagi, M., Matsuo, M., & Iijima,
K. (2014). Differences in carrier frequency between mothers of Duchenne and Becker
muscular dystrophy patients. Journal of Human Genetics, 59(1), 46–50.
https://doi.org/10.1038/jhg.2013.119
19. Soltanzadeh, P., Friez, M. J., Dunn, D., von Niederhausern, A., Gurvich, O. L.,
Swoboda, K. J., … Flanigan, K. M. (2010). Clinical and genetic characterization of
manifesting carriers of DMD mutations. Neuromuscular Disorders: NMD, 20(8),
499–504. https://doi.org/10.1016/j.nmd.2010.05.010
20. Moser, H., & Emery, A. E. (1974). The manifesting carrier in Duchenne muscular
dystrophy. Clinical Genetics, 5(4), 271–284.
21. Darras, B. T., Miller, D. T., & Urion, D. K. (1993). Dystrophinopathies. In M. P.
Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. Bean, H. C. Mefford, … N.
Ledbetter (Eds.), GeneReviews(®). Seattle (WA): University of Washington, Seattle.
Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK1119/
22. Viggiano, E., Ergoli, M., Picillo, E., & Politano, L. (2016). Determining the role of
skewed X-chromosome inactivation in developing muscle symptoms in carriers of
Duchenne muscular dystrophy. Human Genetics, 135(7), 685–698.
https://doi.org/10.1007/s00439-016-1666-6
23. Vo, A. H., & McNally, E. M. (2015). Modifier genes and their effect on Duchenne
muscular dystrophy. Current Opinion in Neurology, 28(5), 528–534.
https://doi.org/10.1097/WCO.0000000000000240
24. Florian, A., Rösch, S., Bietenbeck, M., Engelen, M., Stypmann, J., Waltenberger, J.,
… Yilmaz, A. (2016). Cardiac involvement in female Duchenne and Becker muscular

41

dystrophy carriers in comparison to their first-degree male relatives: a comparative
cardiovascular magnetic resonance study. European Heart Journal Cardiovascular
Imaging, 17(3), 326–333. https://doi.org/10.1093/ehjci/jev161
25. Hoogerwaard, E. M., van der Wouw, P. A., Wilde, A. A., Bakker, E., Ippel, P. F.,
Oosterwijk, J. C., … de Visser, M. (1999). Cardiac involvement in carriers of
Duchenne and Becker muscular dystrophy. Neuromuscular Disorders: NMD, 9(5),
347–351.
26. Bogue, L., Peay, H., Martin, A., Lucas, A., & Ramchandren, S. (2016). Knowledge of
carrier status and barriers to testing among mothers of sons with Duchenne or Becker
muscular dystrophy. Neuromuscular Disorders: NMD, 26(12), 860–864.
https://doi.org/10.1016/j.nmd.2016.09.008
27. Politano, L., Nigro, V., Nigro, G., Petretta, V. R., Passamano, L., Papparella, S., …
Comi, L. I. (1996). Development of cardiomyopathy in female carriers of Duchenne
and Becker muscular dystrophies. JAMA, 275(17), 1335–1338.
28. Mccaffrey, T., Guglieri, M., Murphy, A. P., Bushby, K., Johnson, A., & Bourke, J. P.
(2017a). Cardiac involvement in female carriers of duchenne or becker muscular
dystrophy. Muscle & Nerve, 55(6), 810–818. https://doi.org/10.1002/mus.25445
29. Mavrogeni, S., Markousis-Mavrogenis, G., Papavasiliou, A., & Kolovou, G. (2015).
Cardiac involvement in Duchenne and Becker muscular dystrophy. World Journal of
Cardiology, 7(7), 410–414. https://doi.org/10.4330/wjc.v7.i7.410
30. Schelhorn, J., Schoenecker, A., Neudorf, U., Schemuth, H., Nensa, F., Nassenstein,
K., … Schlosser, T. (2015). Cardiac pathologies in female carriers of Duchenne

42

muscular dystrophy assessed by cardiovascular magnetic resonance imaging.
European Radiology, 25(10), 3066–3072. https://doi.org/10.1007/s00330-015-3694-3
31. Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats,
T. G., … Heart Rhythm Society. (2005). ACC/AHA 2005 Guideline Update for the
Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the
American College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and
Management of Heart Failure): developed in collaboration with the American College
of Chest Physicians and the International Society for Heart and Lung Transplantation:
endorsed by the Heart Rhythm Society. Circulation, 112(12), e154-235.
https://doi.org/10.1161/CIRCULATIONAHA.105.167586
32. Politano, L., & Nigro, G. (2012). Treatment of dystrophinopathic cardiomyopathy:
review of the literature and personal results. Acta Myologica: Myopathies and
Cardiomyopathies: Official Journal of the Mediterranean Society of Myology, 31(1),
24–30.
33. Bobo, J. K., Kenneson, A., Kolor, K., & Brown, M. A. (2009). Adherence to
american academy of pediatrics recommendations for cardiac care among female
carriers of duchenne and becker muscular dystrophy. Pediatrics, 123(3), e471-475.
https://doi.org/10.1542/peds.2008-2643
34. Bushby, K., Muntoni, F., & Bourke, J. P. (2003). 107th ENMC international
workshop: the management of cardiac involvement in muscular dystrophy and
myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscular
Disorders: NMD, 13(2), 166–172.

43

35. Peay, H. L., Meiser, B., Kinnett, K., Furlong, P., Porter, K., & Tibben, A. (2016).
Mothers’ psychological adaptation to Duchenne/Becker muscular dystrophy.
European Journal of Human Genetics: EJHG, 24(5), 633–637.
https://doi.org/10.1038/ejhg.2015.189
36. Hatzmann J, Heymans HSA, Ferrer-i-Carbonell A, van Praag BMS, Grootenhuis MA.
Hidden consequences of success in pediatrics: parental health-related quality of life-results from the Care Project. Pediatrics. 2008;122(5):e1030-1038.
doi:10.1542/peds.2008-0582

44

APPENDIX A:
WEB-BASED QUESTIONNAIRE
This is a research project being conducted by Lauren Eekhoff at the University of
South Carolina in Columbia, SC. The purpose of this research project is to identify the
challenges that women who are known to be carriers of Duchenne or Becker Muscular
Dystrophy (DBMD) experience in obtaining cardiac surveillance. You are invited to take
this questionnaire if you have a living or deceased son with Duchenne or Becker
Muscular Dystrophy and you have been found to be a carrier.
This study contains two parts: 1) a 10-minute questionnaire intended to determine
if you are a carrier of DBMD 2) a 30-minute phone interview in which you will be asked
questions regarding the specific challenges that you experience in obtaining cardiac care.
This is the main focus and vital piece of the study, and if you would be willing to
participate in an interview, there will be a designated location at the end of the
questionnaire where you can provide your contact information. Your responses will be
kept confidential. The results of this study will be used for scholarly purposes only.
Your participation in this research study is voluntary. You may choose not to
participate. If you decide to participate in this research study, you may withdraw at any
time. If you decide not to participate in this study or if you withdraw from participating at
any time, you will not be penalized.
Please complete this questionnaire only once. If you do not reach the “Thank you
for completing the survey” page at the end, your responses may not be included in the
final analysis.
*1. Clicking on the "agree" button below indicates that:
• you have read the above information
• you voluntarily agree to participate
• you are at least 18 years of age
If you do not wish to participate in the research study, please decline participation by
clicking on the "disagree" button.
2. Check the box next to the one statement that applies to you:
I have a living son (or sons) with Duchenne or Becker Muscular Dystrophy
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I no longer have any living sons with Duchenne or Becker Muscular Dystrophy
I have never had any sons with Duchenne or Becker Muscular Dystrophy
3. Check the box next to the statement that best describes you:
I know my carrier status, and I am a Duchenne or Becker Muscular Dystrophy carrier
I know my carrier status, and I am not a Duchenne or Becker Muscular Dystrophy
carrier
I do not know my carrier status
I am not sure what this question is asking
4. How did you confirm your carrier status? Select all that apply.
I had genetic testing
I had a blood test but I am not sure if it was genetic testing
of

I am an obligate carrier (meaning that my carrier status is certain based on the pattern
affected boys in my family)
A physician told me
A genetic counselor told me
I am not sure
Other method (please specify)

5. Please tell us the most recent time (month and year) you...
…saw a cardiologist
…had an ECG (test that checks the heart rhythm)
…had an echocardiogram or cardiac MRI (tests that look at the heart)
6. How many sons with Duchenne or Becker do you/did you have? Include those who are
deceased.
Zero
One
Two or more
7. Mark the statement which is most true for you and your extended family. In choices B
and C, consider “my son” to mean your first affected son if you have had more than one
son with Duchenne or Becker.
a. My son (or sons) is the only person in the family with Duchenne or Becker.
b. My son was the only person in the family with Duchenne or Becker at the time he
was diagnosed, but since then, at least one other family member (not another son of my
own) has been diagnosed with Duchenne or Becker Muscular Dystrophy
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c. My son was not the first person in the family to be diagnosed with Duchenne or
Becker; there was a family history of the condition prior to my pregnancy with my son.
d. I am not sure / none of these seem true for my family
8. This study includes an interview conducted via phone call that will last approximately
30-40 minutes. Your participation is greatly appreciated and your responses invaluable to
this study. Would you be willing to participate in the interview portion of this study?
o Yes
o No
9. Please provide your preferred contact information so that we may contact you to set up
the interview for this study. Your contact information will not be linked to your
responses. Participation is voluntary.
Name:
Email:
Cell Phone:
Home Phone:

Questionnaire used with permission from Bogue et al., 2016.
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APPENDIX B:
INTERVIEW QUESTIONS
Carrier Status Discovery (Educational Barrier)
1. Tell me about the time when you discovered you were a carrier of muscular
dystrophy.
a. When? (How many years ago was this?)
b. How old were you?
c. Was this the same time that your son was diagnosed?
d. Who informed you of your carrier status?
e. What information did you receive during that diagnosis? How was it
explained to you?
f. Do you feel that the information you received was sufficient at that time or
were you left with questions?
g. Do you know who to contact if you do have questions?
h. Were you referred for a complete cardiac evaluation at that time of
diagnosis?
Self-care Current Practices (Perceived Risk Barrier)
1. Are you aware of any health risks associated with being a carrier of MD?
2. How concerned are you with the health risks associated with being a carrier?
3. Are you aware of the American Academy of Pediatrics’ recommendations for
carriers of MD? (cardiac eval every 5 years)
a. How important is it to you to follow the AAP recommendations for
cardiac evaluation?
b. Have you ever been seen by a cardiologist?
c. When was the last time you had an ECG and/or an echocardiogram? A
cardiac MRI?
Barriers/Challenges (Relationship with healthcare provider, lack of support, access to
healthcare, emotional burden, denial? Barriers)
1. What are your reasons for having (not having) an ECG and/or echocardiogram?
2. Tell me about your relationship with your primary healthcare provider.
a. Is he/she aware of your carrier status?
b. How frequently do you discuss your carrier status/associated health risks?
3. Do you have any other females in your family that have had genetic testing and
are carriers of muscular dystrophy?
a. What is your relationship like with them?
b. Do you feel comfortable discussing matters related to your own health
with them
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4. Tell me about your access to cardiac care/a cardiologist.
a. Is it easy for you to get to your appointments?
b. How long does it take you to get to a cardiologist?
c. What is your relationship like with your cardiologist?
d. Do you feel comfortable asking him/her any questions you may have?
5. Tell me about being a mother of a child with a condition like muscular dystrophy.
a. Do you attend all his healthcare appointments with him?
b. Do any of the specialists ever discuss your own cardiac health issues?
c. Many mothers have to balance their family’s health care need with taking
care of their own health care needs. Oftentimes, mom’s healthcare needs
get put on the back-burner. How is this for you?
6. Tell me about the routine healthcare screenings you partake in annually.
a. When was your last mammogram, colonoscopy, physical, etc.?
7. The ultimate goal of this study is to raise awareness of healthcare professionals
about the needs of carriers of DBMD. What do you want your cardiologist,
genetic counselor, etc. to know about your healthcare needs? Is there any way you
can think that would help us serve you better?
Demographics
8. What is your age?
9. What is your ethnicity?
10. What is your race?
11. What is your current occupation?
12. What is the highest level of education you have completed?
13. Where do you live? (city; rural/urban?)
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APPENDIX C:
MAJOR THEMES AND REPRESENTATIVE QUOTES
Carriers experience a lack of
Carriers are responsible for
awareness regarding cardiac risks educating themselves about risks
among healthcare providers in
associated with being a carrier and
general.
are their own advocates.

Anyway they’re not familiar around
here with this disease where I live.

I guess they’ve felt like you know an
EKG and then a Holter monitor worn
for twenty-four hours was was enough
to give them you know the information
they needed.

I don’t know how to deal with
physicians cuz like I said you’ve got
some physicians that test you and
they’re way proactive and look things
up and then you’ve got other
physicians who deal with it all the
time... And you kinda have to tell them
what the recommendation is.
Each cardiologist is like, “I have no
idea why you’re here.” And I explain
to them because of muscular
dystrophy if I’m a carrier that means I
may have cardiomyopathy I think it is
and then something with my kidneys.
Yep and both of them had no idea
what I was talking about.

Carriers are frustrated with the
misinformation regarding cardiac
risks.

You know I didn’t know about that
[increased cardiac risks], and actually
she [my mother] didn’t know about
that until I did research. I got really
curious about it, and I wanted to know,
you know, all about it and about being
a carrier and all that.

When they say I’m a carrier and there’s
a risk for cardiomyopathy like what does
that really mean? Like is it because of the
amount of deletion genes that I’m
missing? Like yeah I think it’s just
understanding that more and being more
aware of that.

It’s more for myself initiating it
[cardiologist appointments].

I’d like to be educated on uhm perhaps
specifically what tests should be done
every five years. That was like big news
to me that you told me that. Uhm and I
would say uhm like what symptoms to
look out for in general. Uhm and in
terms of cardiac uhm and also be to
being aware of uhm the appropriate
resources that I can do to get more
information or more support.

When I make an appointment again I’m
going to make sure that I have my
How it was framed it was like, “This
son’s doctor, Shanti’s doctor, write
isn’t an issue until you decide to have
something down or I don’t know find children,” which I think is like generally
something electronic to my cardiologist true uhm but I kinda wish with that there
to let them know why I’m coming in
had been a little bit more of
for testing. Or I guess it’s like people
conversation.
aren’t familiar with it.

Where I found out about uhm what
carrier care I needed was from the
MDA website.
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Do cardiologists actually see people like
me for that reason?

Carriers are unconcerned about cardiac
Carriers tend to put the needs
Some carriers experience a lack of
Carriers believe conversations about
risks due to perceived healthy lifestyles
of their family members
openness with other family
carrier status and associated risks should
or a lack of a family history of cardiac
before their own healthcare
members who are also carriers.
begin at an earlier age.
events.
needs.

I’m not too worried about it. Uhm I don’t
And I think if my mom found out she
have any like. With my mom being a carrier,
was a carrier it probably would be
she’s never even had. Actually after she
devastating for her. That’s why in the
found out she’s a carrier, they did a workup
very beginning I never said you should
on her heart. She’s never had any problems
get tested too.
so I’m really not worried about it.

So how much time do we spend If my mother had knew [about my carrier
caregiving? 24/7 yeah. And
status] and she had explained it to me when I
that’s that’s really both my
was growing up and everything that might
husband and me spending
have saved me a lot of always being a
essentially all of our time
mystery every time I went to the doctor about
caregiving for these adorable you know what was going on with my body
kids who absolutely deserve it.
and all that.

They will not allow us to test for her [my
She [my mother] didn’t have any real
I was trying to work a job. I was
daughter] because she’s not of age of
cardiac you know. And so my grandmother
trying to take care of him. I
I think it was hard for her [my mother]
consent until she turns 18 and I was a little bit
who would’ve been a carrier didn’t have
never had time for myself. I
to talk about so she never said
upset about that but you know I was like well
any you know cardiac issues….I felt like
never had time to take myself to
anything.
I’m not saying that she would but say if she
because of the family history that I’m not
the doctor. I never had time to
would get pregnant at 13, I would like to
really at risk for it.
uhm to really care for myself.
know so that I can educate my daughter.

I feel like my dad is able to talk more
about it. I will say like there is a part of
me that feels uhm like hesitant or kinda
It’s just like in our family like I mean yeah
shy away from bringing it up with him
there’s been heart issues but like nothing’s
uhm I think because there’s this
been directly linked to muscular dystrophy.
dynamic of both my parents were in
So like it’s never really concerned me.
healthcare and I think they adopted
this, “Unless you’re seriously sick
you’re totally fine.”

She [mom] thinks all this is her fault.
I try to eat you know well and everything. I
She doesn’t understand the genetics
exercise at least 4 to 5 times a week. At
and I explained to her the science and
least I’m exercising and things like that. So
the genetics, “This is not your
you know just try to keep myself healthy as
fault.”...they don’t understand that and
possible.
neither do her sisters

51

Things like that where something
is like you know I have an injury
or something. I’m kinda like,
“Eh whatever. I’ll wait until it
gets worse or whatever.” Cuz I
mainly want him and my
daughter like their whatever their
appointments and their stuff first
and I’ll deal with myself later.

